WallStreetZenWallStreetZen

NASDAQ: TMDX
Transmedics Group Inc Stock Forecast, Predictions & Price Target

Analyst price target for TMDX

Based on 5 analysts offering 12 month price targets for Transmedics Group Inc.
Min Forecast
$39.00-43.77%
Avg Forecast
$48.00-30.8%
Max Forecast
$63.00-9.17%

Should I buy or sell TMDX stock?

Based on 5 analysts offering ratings for Transmedics Group Inc.
Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TMDX stock forecasts and price targets.

TMDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Morgan Stanley
Bottom 34%
34
HoldMaintains$63.00-9.17%2023-01-06
Oppenheimer
Bottom 7%
7
BuyMaintains$45.00-35.12%2022-08-02
JP Morgan
Bottom 36%
36
Strong BuyUpgrades$48.00-30.80%2022-08-02
Cowen & Co.
Top 16%
85
BuyMaintains$45.00-35.12%2022-07-26
Canaccord Genuity
Bottom 11%
11
Strong BuyMaintains$39.00-43.77%2022-03-17
Anonymous
Morgan Stanley
HoldMaintains$15.00-78.37%2022-02-25

1 of 1

Forecast return on equity

Is TMDX forecast to generate an efficient return?
Company
-12.07%
Industry
16.12%
Market
47.84%
TMDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TMDX forecast to generate an efficient return on assets?
Company
-8.25%
Industry
10.43%
TMDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TMDX earnings per share forecast

What is TMDX's earnings per share in the next 2 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.98
Avg 2 year Forecast
-$0.71

TMDX revenue forecast

What is TMDX's revenue in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$107.8M+50.23%
Avg 2 year Forecast
$142.3M+98.26%
TMDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TMDX revenue growth forecast

How is TMDX forecast to perform vs Medical Devices companies and vs the US market?
Company
50.23%
Industry
10.68%
Market
70.6%
TMDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TMDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TMDX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
TMDX$69.36$48.00-30.80%Buy
SILK$54.81$42.50-22.46%Hold
ITGR$73.50$84.00+14.29%Strong Buy
NUVA$48.12$51.82+7.68%Buy
CTKB$13.39$16.00+19.49%Strong Buy

Transmedics Group Stock Forecast FAQ

Is Transmedics Group Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: TMDX) stock is to Buy TMDX stock.

Out of 5 analysts, 2 (40%) are recommending TMDX as a Strong Buy, 2 (40%) are recommending TMDX as a Buy, 1 (20%) are recommending TMDX as a Hold, 0 (0%) are recommending TMDX as a Sell, and 0 (0%) are recommending TMDX as a Strong Sell.

If you're new to stock investing, here's how to buy Transmedics Group stock.

What is TMDX's earnings growth forecast for 2023-2024?

(NASDAQ: TMDX) Transmedics Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 91.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 84.98%.

Transmedics Group's earnings in 2023 is -$42,179,000.On average, 4 Wall Street analysts forecast TMDX's earnings for 2023 to be -$31,285,736, with the lowest TMDX earnings forecast at -$39,586,033, and the highest TMDX earnings forecast at -$21,708,470.

In 2024, TMDX is forecast to generate -$22,666,196 in earnings, with the lowest earnings forecast at -$35,435,884 and the highest earnings forecast at -$9,896,508.

What is TMDX's revenue growth forecast for 2023-2024?

(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 50.23% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 10.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.6%.

Transmedics Group's revenue in 2023 is $71,752,000.On average, 3 Wall Street analysts forecast TMDX's revenue for 2023 to be $3,441,111,674, with the lowest TMDX revenue forecast at $3,194,656,695, and the highest TMDX revenue forecast at $3,840,483,666.

In 2024, TMDX is forecast to generate $4,541,443,765 in revenue, with the lowest revenue forecast at $4,216,710,599 and the highest revenue forecast at $4,866,208,855.

What is TMDX's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: TMDX) forecast ROA is -8.25%, which is lower than the forecast US Medical Devices industry average of 10.43%.

What is TMDX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year TMDX price target, the average TMDX price target is $48.00, with the highest TMDX stock price forecast at $63.00 and the lowest TMDX stock price forecast at $39.00.

On average, Wall Street analysts predict that Transmedics Group's share price could fall to $48.00 by Jan 6, 2024. The average Transmedics Group stock price prediction forecasts a potential downside of 30.8% from the current TMDX share price of $69.36.

What is TMDX's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: TMDX) Transmedics Group's current Earnings Per Share (EPS) is -$1.50. On average, analysts forecast that TMDX's EPS will be -$0.98 for 2023, with the lowest EPS forecast at -$1.24, and the highest EPS forecast at -$0.68. In 2024, TMDX's EPS is forecast to hit -$0.71 (min: -$1.11, max: -$0.31).

What is TMDX's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: TMDX) forecast ROE is -12.07%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.